Assembly Biosciences Provides Anticipated Development Milestones for 2024
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024.
Related news for (ASMB)
- Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
- Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
- New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
- Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
- Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights